Oxygen effects on glucose measurements with a reference analyzer and three handheld meters

Z. Tang, R. F. Louie, M. Payes, K. C J Chang, Gerald J Kost

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Oxygen may affect glucose meter and reference analyzer measurements. We evaluated the effects of changes in blood oxygen tension (Po2) on Accu-Chek Comfort Curve (Roche Diagnostics, Indianapolis, IN),(TM) Precision G,(TM) (Abbott Laboratories, Bedford, MA) and One Touch II® (Lifescan, Milpitas, CA) glucose meter measurements, and on Yellow Springs Instruments (YSI) (Yellow Springs, OH) reference analyzer measurements. Venous blood drawn from healthy volunteers was adjusted to three glucose levels of 80, 200, and 400 mg/dL, each tonometered with six different Po2 levels (40, 80, 160, 240, 320, and 400 torr). To quantitate oxygen effects on reference analyzer measurements, glucose differences between test sample (Po2 changed) and control (Po2 80 torr) were calculated (YSI(test)-YSI(control)). The threshold for determination of oxygen effects was ±2 SD, where 2 SD was from YSI between-day precision evaluated with aqueous controls. To quantitate oxygen effects on glucose meter measurements, paired-differences between glucose meter and reference analyzer measurements were calculated (Meter-YSI). Error tolerances for determination of oxygen effects were (a) within ±15 mg/dL of reference measurement at glucose levels ≤100 mg/dL, and (b) within ±15% of reference measurement at glucose levels >100 mg/dL. All differences for the reference analyzer measurements were within ±2 SD ranges. Increases in Po2 lowered Precision G measurements. Differences exceeding the error tolerances (±15 mg/dL or ±15%) were mainly at Po2 levels >100 torr. Glucose differences for the Accu-Chek Comfort Curve and One Touch II were within the error tolerances. Changes in Po2 do not affect glucose measurements with the YSI reference analyzer, Accu-Chek Comfort Curve, and One Touch meter systems. High blood Po2 levels (>100 torr) significantly decrease Precision G measurements. We recommend that health care professionals understand oxygen effects and use oxygen-insensitive meter systems for point-of-care glucose testing when patients are on oxygen ventilation or critically ill.

Original languageEnglish (US)
Pages (from-to)349-362
Number of pages14
JournalDiabetes Technology and Therapeutics
Volume2
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Oxygen
Glucose
Touch
Blood
Critical Illness
Ventilation
Health care
Healthy Volunteers
Delivery of Health Care
Testing

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Oxygen effects on glucose measurements with a reference analyzer and three handheld meters. / Tang, Z.; Louie, R. F.; Payes, M.; Chang, K. C J; Kost, Gerald J.

In: Diabetes Technology and Therapeutics, Vol. 2, No. 3, 2000, p. 349-362.

Research output: Contribution to journalArticle

Tang, Z. ; Louie, R. F. ; Payes, M. ; Chang, K. C J ; Kost, Gerald J. / Oxygen effects on glucose measurements with a reference analyzer and three handheld meters. In: Diabetes Technology and Therapeutics. 2000 ; Vol. 2, No. 3. pp. 349-362.
@article{1799d0e8d94b48ddb42c6089560b9c0c,
title = "Oxygen effects on glucose measurements with a reference analyzer and three handheld meters",
abstract = "Oxygen may affect glucose meter and reference analyzer measurements. We evaluated the effects of changes in blood oxygen tension (Po2) on Accu-Chek Comfort Curve (Roche Diagnostics, Indianapolis, IN),(TM) Precision G,(TM) (Abbott Laboratories, Bedford, MA) and One Touch II{\circledR} (Lifescan, Milpitas, CA) glucose meter measurements, and on Yellow Springs Instruments (YSI) (Yellow Springs, OH) reference analyzer measurements. Venous blood drawn from healthy volunteers was adjusted to three glucose levels of 80, 200, and 400 mg/dL, each tonometered with six different Po2 levels (40, 80, 160, 240, 320, and 400 torr). To quantitate oxygen effects on reference analyzer measurements, glucose differences between test sample (Po2 changed) and control (Po2 80 torr) were calculated (YSI(test)-YSI(control)). The threshold for determination of oxygen effects was ±2 SD, where 2 SD was from YSI between-day precision evaluated with aqueous controls. To quantitate oxygen effects on glucose meter measurements, paired-differences between glucose meter and reference analyzer measurements were calculated (Meter-YSI). Error tolerances for determination of oxygen effects were (a) within ±15 mg/dL of reference measurement at glucose levels ≤100 mg/dL, and (b) within ±15{\%} of reference measurement at glucose levels >100 mg/dL. All differences for the reference analyzer measurements were within ±2 SD ranges. Increases in Po2 lowered Precision G measurements. Differences exceeding the error tolerances (±15 mg/dL or ±15{\%}) were mainly at Po2 levels >100 torr. Glucose differences for the Accu-Chek Comfort Curve and One Touch II were within the error tolerances. Changes in Po2 do not affect glucose measurements with the YSI reference analyzer, Accu-Chek Comfort Curve, and One Touch meter systems. High blood Po2 levels (>100 torr) significantly decrease Precision G measurements. We recommend that health care professionals understand oxygen effects and use oxygen-insensitive meter systems for point-of-care glucose testing when patients are on oxygen ventilation or critically ill.",
author = "Z. Tang and Louie, {R. F.} and M. Payes and Chang, {K. C J} and Kost, {Gerald J}",
year = "2000",
doi = "10.1089/15209150050194215",
language = "English (US)",
volume = "2",
pages = "349--362",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Oxygen effects on glucose measurements with a reference analyzer and three handheld meters

AU - Tang, Z.

AU - Louie, R. F.

AU - Payes, M.

AU - Chang, K. C J

AU - Kost, Gerald J

PY - 2000

Y1 - 2000

N2 - Oxygen may affect glucose meter and reference analyzer measurements. We evaluated the effects of changes in blood oxygen tension (Po2) on Accu-Chek Comfort Curve (Roche Diagnostics, Indianapolis, IN),(TM) Precision G,(TM) (Abbott Laboratories, Bedford, MA) and One Touch II® (Lifescan, Milpitas, CA) glucose meter measurements, and on Yellow Springs Instruments (YSI) (Yellow Springs, OH) reference analyzer measurements. Venous blood drawn from healthy volunteers was adjusted to three glucose levels of 80, 200, and 400 mg/dL, each tonometered with six different Po2 levels (40, 80, 160, 240, 320, and 400 torr). To quantitate oxygen effects on reference analyzer measurements, glucose differences between test sample (Po2 changed) and control (Po2 80 torr) were calculated (YSI(test)-YSI(control)). The threshold for determination of oxygen effects was ±2 SD, where 2 SD was from YSI between-day precision evaluated with aqueous controls. To quantitate oxygen effects on glucose meter measurements, paired-differences between glucose meter and reference analyzer measurements were calculated (Meter-YSI). Error tolerances for determination of oxygen effects were (a) within ±15 mg/dL of reference measurement at glucose levels ≤100 mg/dL, and (b) within ±15% of reference measurement at glucose levels >100 mg/dL. All differences for the reference analyzer measurements were within ±2 SD ranges. Increases in Po2 lowered Precision G measurements. Differences exceeding the error tolerances (±15 mg/dL or ±15%) were mainly at Po2 levels >100 torr. Glucose differences for the Accu-Chek Comfort Curve and One Touch II were within the error tolerances. Changes in Po2 do not affect glucose measurements with the YSI reference analyzer, Accu-Chek Comfort Curve, and One Touch meter systems. High blood Po2 levels (>100 torr) significantly decrease Precision G measurements. We recommend that health care professionals understand oxygen effects and use oxygen-insensitive meter systems for point-of-care glucose testing when patients are on oxygen ventilation or critically ill.

AB - Oxygen may affect glucose meter and reference analyzer measurements. We evaluated the effects of changes in blood oxygen tension (Po2) on Accu-Chek Comfort Curve (Roche Diagnostics, Indianapolis, IN),(TM) Precision G,(TM) (Abbott Laboratories, Bedford, MA) and One Touch II® (Lifescan, Milpitas, CA) glucose meter measurements, and on Yellow Springs Instruments (YSI) (Yellow Springs, OH) reference analyzer measurements. Venous blood drawn from healthy volunteers was adjusted to three glucose levels of 80, 200, and 400 mg/dL, each tonometered with six different Po2 levels (40, 80, 160, 240, 320, and 400 torr). To quantitate oxygen effects on reference analyzer measurements, glucose differences between test sample (Po2 changed) and control (Po2 80 torr) were calculated (YSI(test)-YSI(control)). The threshold for determination of oxygen effects was ±2 SD, where 2 SD was from YSI between-day precision evaluated with aqueous controls. To quantitate oxygen effects on glucose meter measurements, paired-differences between glucose meter and reference analyzer measurements were calculated (Meter-YSI). Error tolerances for determination of oxygen effects were (a) within ±15 mg/dL of reference measurement at glucose levels ≤100 mg/dL, and (b) within ±15% of reference measurement at glucose levels >100 mg/dL. All differences for the reference analyzer measurements were within ±2 SD ranges. Increases in Po2 lowered Precision G measurements. Differences exceeding the error tolerances (±15 mg/dL or ±15%) were mainly at Po2 levels >100 torr. Glucose differences for the Accu-Chek Comfort Curve and One Touch II were within the error tolerances. Changes in Po2 do not affect glucose measurements with the YSI reference analyzer, Accu-Chek Comfort Curve, and One Touch meter systems. High blood Po2 levels (>100 torr) significantly decrease Precision G measurements. We recommend that health care professionals understand oxygen effects and use oxygen-insensitive meter systems for point-of-care glucose testing when patients are on oxygen ventilation or critically ill.

UR - http://www.scopus.com/inward/record.url?scp=0033764601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033764601&partnerID=8YFLogxK

U2 - 10.1089/15209150050194215

DO - 10.1089/15209150050194215

M3 - Article

C2 - 11467337

AN - SCOPUS:0033764601

VL - 2

SP - 349

EP - 362

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 3

ER -